


**Product Name** : Dalpiciclib  
**Cat. No.** : PC-38355  
**CAS No.** : 1637781-04-4  
**Molecular Formula** : C<sub>25</sub>H<sub>30</sub>N<sub>6</sub>O<sub>2</sub>  
**Molecular Weight** : 446.555  
**Target** : Cyclin-dependent Kinase (CDK)  
**Solubility** : 10 mM in DMSO



### Biological Activity

Dalpiciclib (SHR6390) is an orally bioavailable, small molecule **CDK4/6** inhibitor, strongly inhibits tumor proliferation of ESCC in vitro and in vivo.

SHR6390 inhibits the proliferation of retinoblastoma-positive tumor cell lines, inhibits the CDK4/6-RB pathway and induces G1-phase cell cycle arrest and cellular senescence.

HR6390 combined with PTX or CDDP offered synergistic inhibitory effects in ESCC xenografts.

### References

Long F, et al. *Cancer Sci.* 2019 Apr;110(4):1420-1430.

Wang J, et al. *J Transl Med.* 2017 Jun 2;15(1):127.

Chen Z, et al. *Clin Transl Med.* 2020 Aug;10(4):e148.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com